Altawalbeh SM, et al. - In this retrospective case-control study, researchers focused on the clinical and economic burden related to respiratory tract infection (RTI)-induced asthma exacerbations. They also investigated risk factors associated with these exacerbations. Over the period 2013–2016, they analyzed medical records and pharmacy data in King Abdullah University Hospital in Northern Jordan for adults with asthma aged 40 years and older. A total of 137 cases of RTI-induced asthma exacerbations and 548 controls (selected randomly from asthmatic adults who did not experience any RTI-induced asthma exacerbation during the same period) were included. A significant association was observed between the use of inhaled corticosteroid + long-acting beta-agonists (ICS + LABA) and lower odds of RTI-induced asthma exacerbations as well as lower odds of resultant serious complications, than being untreated with any asthma maintenance treatment. Increased susceptibility to exacerbations was noted in association with asthma severity and co-morbidities. RTI-induced asthma admissions and outpatient exacerbations on average cost 1042.9 JD ($1471.0) and 81.1 JD ($114.4), respectively.